Docosanoic acid

Synopsis

Docosanoic Acid (Behenic Acid): A Comprehensive Reference

1. Identity and Chemical Characterization

Names and Classification

Behenic acid, systematically known as docosanoic acid, is a long-chain saturated fatty acid consisting of a 22-carbon unbranched chain with a carboxylic acid group at one end and the molecular formula C₂₂H₄₄O₂. It is denoted in lipid shorthand notation as C22:0 and is classified within the subgroup of very long-chain fatty acids (VLCFAs), which encompass fatty acids with 20 or more carbon atoms.

The compound is known under a range of synonyms in the scientific and commercial literature. Its IUPAC name is docosanoic acid; CAS registry number 112-85-6; PubChem CID 8215. Other names include docosoic acid, 1-docosanoic acid, and N-docosanoic acid.

The name "behenic" derives from the Persian month Bahman, when the roots of the Moringa tree were harvested. It belongs to the group of saturated fatty acids, carrying no double bond — hence its shorthand notation 22:0.

Physical and Chemical Properties

It presents as a white to off-white waxy solid that is insoluble in water but soluble in organic solvents such as ethanol and chloroform, with a melting point of 80 °C and a boiling point of 306 °C at reduced pressure.

The molecular structure features a straight, unbranched carbon backbone with all single covalent bonds between carbon atoms, confirming its fully saturated nature and absence of double or triple bonds. This saturation distinguishes behenic acid from unsaturated C22 fatty acids, such as erucic acid, which contains a cis double bond. The carboxylic acid group at one end imparts polarity, while the long hydrophobic alkyl chain contributes to its overall amphiphilic properties.

Industrial Production

Behenic acid is primarily produced industrially through the hydrogenation of erucic acid, a monounsaturated C22:1 fatty acid derived from high-erucic acid rapeseed (HEAR) oil, which saturates the double bond to yield behenic acid (C22:0). This process typically involves catalytic hydrogenation under controlled temperature and pressure conditions. HEAR oil, containing 45–55% erucic acid, serves as the main feedstock, sourced from Brassicaceae oilseeds such as Brassica napus cultivars. Alternative production methods include fractional distillation of hydrolyzed vegetable oils rich in behenic acid, such as those from peanuts (containing about 3% behenic acid) or moringa seeds (up to 7–8% behenic acid), where oils are saponified and the resulting fatty acid mixtures are separated by vacuum distillation to isolate the C22 fraction.

2. Natural Sources

Primary Botanical Sources

At 9%, behenic acid is a major component of ben oil (or behen oil), which is extracted from the seeds of the drumstick tree (Moringa oleifera). It is so named from the Persian month Bahman, when the roots of this tree were harvested. Behenic acid is also present in some other oils and oil-bearing plants, including rapeseed (canola) and peanut oil and skins. It is estimated that one ton of peanut skins contains 13 pounds (5.9 kg) of behenic acid.

Pracaxi oil (from the seeds of Pentaclethra macroloba) is a natural product with one of the highest concentrations of behenic acid, and is used in hair conditioners.

Naturally occurring in trace to moderate amounts in various plant-derived oils, behenic acid is a minor component of peanut oil (approximately 3.2 g per 100 g of oil), rapeseed (canola) oil, soybean oil, and moringa seed oil, where it contributes to the overall lipid profile of these fats.

Moringa Species Variation

The degummed oil of Moringa peregrina from Saudi Arabia contained ten fatty acids including behenic acid at approximately 2.36%, along with oleic acid (70.52%), palmitic acid (8.90%), and stearic acid (3.82%) as major components. Analysis of seed oil from another collection showed oleic acid as the major fatty acid (74.81%) followed by palmitic acid (8.95%), with behenic acid present at 2.59%.

Behenic acid is also found in some lichens and can be purified from them using an analytical method involving constant-pressure liquid chromatography.

Presence in the Human Stratum Corneum

Docosanoic acid is not merely a dietary compound — it is a naturally occurring constituent of human skin. Fatty acids naturally present in the human stratum corneum are mostly saturated docosanoic acid (22:0), lignoceric acid (24:0), and hexacosanoic acid (26:0), which are often branched, methylated, and/or hydroxylated, although smaller quantities of oleic acid and linoleic acid have also been reported.

3. Traditional and Historical Use

Moringa in Traditional Medicine

The primary vehicle through which docosanoic acid has been encountered in traditional practice is ben oil (behen oil) pressed from the seeds of Moringa oleifera. Behenic acid is a major component of ben oil, also known as behen oil or Moringa oil (first reported by Voelcker A. in 1848), which is extracted from the seeds of Moringa oleifera and used in cosmetics.

Moringa peregrina is one species which has a wide range of traditional, nutritional, industrial, and medicinal values. Plant parts are used in folk medicine for many human health care purposes including diabetes, wound healing, disinfectant, fever, constipation, muscle pains, slimness, burns, labor pain, hypertension, malaria, stomach disorder, asthma, skin problems, and to expel a retained placenta. In addition to medicinal value, M. peregrina has cultural, spiritual, and religious connections with the native people of the Arabian Peninsula.

The broader traditional uses of Moringa oil, of which behenic acid is a key fatty-acid component, were extensive across South Asia and the Arabian Peninsula. Various parts of the Moringa plant such as leaves, roots, seed, bark, fruit, flowers, and immature pods act as cardiac and circulatory stimulants, and possess antitumor, antipyretic, antiepileptic, anti-inflammatory, antiulcer, antispasmodic, diuretic, antihypertensive, cholesterol-lowering, antioxidant, antidiabetic, hepatoprotective, antibacterial, and antifungal activities, and are employed for the treatment of different ailments in the indigenous system of medicine, particularly in South Asia.

Early Scientific Identification and Historical Commercial Use

First isolated from Ben oil, which is pressed from moringa seeds, the ingredient owes its common name to the tree's former botanical classification, Moringa behen. Chemists began exploring behenic acid in the early 1900s while looking for stable fats that could improve the texture of soaps and creams.

It is important to note that the documented traditional medicinal uses described above pertain to the whole plant or its extracted oil (Moringa oleifera / ben oil), not to isolated docosanoic acid as such. Docosanoic acid as a purified compound has no distinct ancient ethnopharmacological record separate from the plant matrices in which it naturally occurs.

4. Key Constituents and Mechanisms of Action

Identity as a Very Long-Chain Saturated Fatty Acid

Most natural fatty acids have an even number of carbon atoms, because their biosynthesis involves acetyl-CoA, a coenzyme carrying a two-carbon-atom group. Saturated fatty acids do not contain any double bonds or other functional groups along the chain. The term "saturated" refers to hydrogen: all carbons (apart from the carboxylic acid group) contain as many hydrogens as possible. Docosanoic acid, with 22 carbons, sits at the threshold between the "long-chain" and "very long-chain" fatty acid categories, a structural fact that underlies many of its distinctive biological behaviors.

Intestinal Absorption and Bioavailability

In human physiology, behenic acid exhibits poor intestinal absorption due to its extended chain length, which limits its bioavailability compared to shorter-chain fatty acids and results in increased fecal excretion of lipids when consumed. The absorption rate of palmitic acid is approximately 95–98%, while docosanoic acid is considerably lower by comparison. Dietary behenic acid (22:0) is poorly absorbed. Because of its low bioavailability compared with other fatty acids and because of its very long chain length, the effect of dietary behenic acid (behenate) on serum lipid concentrations in humans had historically been assumed to be neutral.

Metabolic Fate

Upon ingestion, behenic acid is absorbed in the intestine and incorporated into chylomicrons, which are then transported to the liver via the lymphatic system. The metabolism of behenic acid involves its breakdown through beta-oxidation, a process that occurs in the mitochondria.

Inhibition of Pancreatic Lipase

Dietary 1(3)-behenoyl-2,3(1)-dioleoyl-rac-glycerol (BOO), a structured triacylglycerol containing behenic acid, has been reported to inhibit pancreatic lipase activity in vitro and suppress postprandial hypertriacylglycerolemia in humans. This inhibitory effect on fat-digesting enzyme activity is one of the most studied mechanistic properties of behenic acid-containing lipids.

Effects on Cholesterol Metabolism

As a dietary oil, behenic acid is poorly absorbed. In spite of its low bioavailability compared with oleic acid, behenic acid is a cholesterol-raising saturated fatty acid in humans. The mechanism by which a poorly absorbed fatty acid raises cholesterol is not fully understood, and the 2001 clinical study by Cater and Denke acknowledged that direct measurement of absorption was not performed. They did not measure behenic acid absorption directly and did not attempt to track behenate metabolism with a tracer, and thus could only speculate about the mechanisms underlying their findings.

Interaction with p53 DNA-Binding Domain

Docosanoic acid inhibits the double-stranded DNA (dsDNA) binding activity of the p53 DNA binding domain, with a Kd of 12 nM. This interaction — identified from preclinical biochemical research — suggests a possible role in cellular gene-regulation pathways, though its physiological significance at nutritionally relevant concentrations is unclear and has not been confirmed in clinical settings.

Role in Sphingolipid and Ceramide Biology

It has been reported that 50% of sphingolipids in myelin contain very-long-chain fatty acids (VLCFAs) (C ≥ 22). This is remarkable considering that VLCFAs are rare fatty acids that make up only 5% of the total fatty acids in the body. An increase in VLCFAs is known to increase membrane stiffness and decrease fluidity, and VLCFAs are thought to be critical for proper myelin function.

Ceramide synthase 2 (CerS2) has affinity for fatty acyl chain lengths of C22–C24 — the range that includes docosanoic acid — and CerS2 is highly expressed in oligodendrocytes during periods of active myelination. Ceramide species with behenic acid (Cer-22) and analogous sphingomyelin species (SM-22) have been studied specifically in relation to brain pathology biomarkers.

Free Fatty Acid Receptor Interactions

Due to a unique mechanism that limits the possibility of hypoglycemia, the free fatty acid receptor (FFA1) is an attractive target for the treatment of type 2 diabetes. In silico studies of fatty acids on the free fatty acid 1 receptor identified that behenic acid was the most potent candidate among four promising fatty acids and showed a binding energy of −110.857 kcal/mol. These are computational findings only and do not constitute clinical evidence.

Anti-Inflammatory Signaling

Behenic acid possesses antioxidant, anti-inflammatory, antibacterial, and antitumor properties and has been shown to be a natural inhibitor of pancreatic lipase, which is effective in suppressing the development of obesity. Current research posits that insulin resistance and chronic inflammation are related to the TLR4/NF-κB signaling pathway, and studies have examined behenic acid's modulation of this pathway.

Antibacterial Activity

Behenic acid has shown antibacterial efficacy against bacteria including Acinetobacter baumannii, Staphylococcus aureus, and Pseudomonas aeruginosa. These findings are from laboratory/in vitro studies and have not been confirmed in clinical infection models.

5. Scientific Evidence by Area of Use

5.1 Cardiovascular System: Cholesterol and Lipid Effects

Clinical Evidence (Human): The most important clinical study of docosanoic acid was published in the American Journal of Clinical Nutrition by Cater and Denke in 2001. The objective was to establish the cholesterol-raising potential of behenic acid by comparing the effects on lipid and lipoprotein concentrations of a specially formulated fat enriched with behenic acid with those of palm oil (rich in palmitic acid; 16:0) and high-oleic acid sunflower oil (rich in oleic acid; 18:1). In a randomized, crossover, metabolic-ward study, 7 mildly hypercholesterolemic men were fed 3 natural-food diets supplemented with behenate oil, palm oil, or high-oleic acid sunflower oil. Mean serum lipid and lipoprotein concentrations and plasma triacylglycerol fatty acid composition were determined from fasting blood drawn during the final 4 days of each 3-week diet period.

The study demonstrated that despite behenic acid's low bioavailability, these fatty acids are cholesterol-raising agents in humans, and therefore are used in topical skin and hair applications mostly for their lubricant and moisturizing properties rather than as dietary supplements. The clinical study was very small (n=7), used a single specially formulated behenate oil, and the investigators acknowledged limitations around mechanistic understanding.

They used only a single formulated fat containing behenic acid, and whether similar findings would have been observed with a different mixture of fatty acids is unknown.

Evidence Strength: Weak. Only a single small randomized crossover study (n=7) in humans. The finding that behenic acid raises LDL cholesterol despite poor absorption remains mechanistically unexplained. No large RCTs exist. The epidemiological context is further complicated by the fact that docosanoic acid occurs only as a minor component in dietary fats, and population-level intake is very low.

5.2 Obesity, Body Weight, and Adipose Tissue

Animal Evidence: The structured triacylglycerol 1(3)-behenoyl-2,3(1)-dioleoyl-rac-glycerol (BOO), in which behenic acid occupies the sn-1 or sn-3 position, has been studied in rodents. A study investigated the anti-obesity activities of BOO and its inhibitory effects on lymphatic triacylglycerol (TAG) absorption in rats. In Experiment 1, rats were fed either BOO or soybean oil (SO) diet for 6 weeks, with 20% of SO replaced with an experimental oil rich in BOO.

Plasma and liver TAG concentrations and visceral fat weights were significantly lower in the BOO group than in the SO group. The apparent absorption rate of fat was significantly lower in the BOO group than in the SO group. These results suggest that BOO prevents deposition of visceral fat and hepatic TAG by lowering and delaying intestinal absorption of TAG.

In a separate mouse study using enzymatically synthesized structured lipids: The objective was to study the anti-obesity effects of structured lipids (SL) obtained by enzymatic interesterification, based on olive oil, soy oil, and fully hydrogenated crambe oil. Twenty-four C57Bl/6 mice were distributed into four experimental groups according to the diet consumed. The animals that were fed SLs presented a smaller weight gain, despite a larger intake of the diet. The lowest weight gain was reflected in reduced amounts of adipose tissue and lower liver weight.

Behenic acid increased the excretion of lipid in the feces. The results showed that animals that consumed structured lipids containing behenic acid showed lower weight gain, due to the significant increase in lipids excreted by the animals in the feces, without any sign of toxicity or the presence of diarrhea. Increased hepatic levels of the HDL-c fraction, arachidonic acid (AA; 20:4n-6) and docosahexaenoic acid (DHA, 22:6n-3), and decreased LDL-c were also observed, demonstrating that there was sufficient absorption of essential fatty acids in the intestine, and suggesting that structured lipids containing behenic acid can be a good alternative in obesity and associated-disease prevention.

A subsequent study in mice concluded that structured lipid containing behenic acid has the ability to reduce postprandial inflammation and can promote health. Behenic acid (C22:0) was detected in the feces of mice that had chronic ingestion of structured lipids containing up to 6% behenic acid, demonstrating partial absorption of this fatty acid when consumed long-term.

Evidence Strength: Preliminary — all evidence is from animal models (rats and mice). No human RCTs exist examining behenic acid-containing structured lipids for weight management outcomes. The mechanism (fat malabsorption via pancreatic lipase inhibition) is biologically plausible but requires clinical validation.

5.3 Diabetes and Glycemic Metabolism

Epidemiological / Observational Evidence: An ancillary study from a randomized clinical trial found an inverse association of both docosanoic (behenic) acid (22:0) and tetracosanoic (lignoceric) acid (24:0) with HbA1c, as higher plasma concentrations of very-long-chain saturated fatty acids have been associated with lower risk of type 2 diabetes. This is an observational association, not a causal demonstration.

In Silico / Computational Evidence: In silico studies of fatty acids on the free fatty acid 1 receptor (FFA1) identified behenic acid as the most potentially active among four evaluated fatty acids, showing binding energy of −110.857 kcal/mol. The stability of the protein-ligand complex was confirmed in simulation studies, with occupancy of 95% and 84% in respective analyses. Behenic acid is present in different parts of the Moringa tree and may serve as medicinal food in type II diabetes mellitus.

Cell/Tissue Study — Gestational Diabetes: A PMC-indexed study investigated behenic acid in the context of gestational diabetes mellitus (GDM). Behenic acid possesses anti-inflammatory and antioxidant properties, and several epidemiological studies have demonstrated that circulating behenic acid concentrations are negatively correlated with the incidence of GDM. TLR4-mediated chronic inflammation induced by the maternal innate immune system during pregnancy can aggravate insulin resistance in pregnant women and eventually lead to GDM.

Evidence Strength: Very preliminary. Evidence for anti-diabetic effects of docosanoic acid consists of in silico docking studies and observational epidemiological associations. No human interventional trials testing behenic acid as a treatment or prevention strategy for diabetes or glycemic control have been conducted.

5.4 Neurological System: Sphingolipids and Myelin

Research Evidence: Docosanoic acid, as a VLCFA, is incorporated into ceramide and sphingomyelin species that are critical constituents of the myelin sheath. Ceramide species with behenic acid (Cer-22) and analogous sphingomyelin species (SM-22) have been studied in the Cardiovascular Health Study (CHS), a large cohort of older adults, through examination of MRI measurements such as white matter hyperintensities, ventricular size, brain atrophy, and circulating biomarkers of brain injury including neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP).

In the fully adjusted model, higher plasma levels of ceramides and sphingomyelins with a long (16-carbon) saturated fatty acid were associated with higher blood levels of NfL. In contrast, sphingomyelins with very long (20- and 22-carbon) saturated fatty acids tended to have an inverse association with levels of circulating NfL. This suggests that sphingomyelins containing docosanoic acid (22-carbon) may be associated with less neuronal injury in older adults, though this is an observational finding only.

Findings in flies and mice indicate that the VL-ceramide pathway is critical in the nervous system and may represent a novel therapeutic target for neurodegenerative diseases associated with sphingolipid metabolism, including multiple sclerosis.

Evidence Strength: Preliminary. Associational data from human cohort studies and mechanistic animal data. No intervention trials involving docosanoic acid supplementation for neurological outcomes exist.

5.5 Skin and Topical Applications

Behenic acid is a texture enhancer widely used in cosmetics to provide richness and viscosity, enhancing the spreadability and stability of products like creams, lotions, and balms. It forms a water-repellent layer on the surface of skin and hair to prevent moisture loss. It is ideal for dry and sensitive skin types, making the skin soft, smooth, and radiant. In products like hair conditioners and hair masks, behenic acid helps tame frizz and flyaways.

Docosanoic acid's presence as a native constituent of the stratum corneum provides biological rationale for its topical use. Fatty acids naturally present in the human stratum corneum are mostly saturated docosanoic acid (22:0), lignoceric acid (24:0), and hexacosanoic acid (26:0). This endogenous presence has been cited to support the cosmetic use of behenic acid in barrier-restoring formulations, though controlled clinical trials of topical docosanoic acid as an isolated ingredient are not well-documented in the peer-reviewed literature.

Evidence Strength: The cosmetic/topical use is well-established industrially and is supported by biologically plausible rationale (native skin constituent, emollient properties). However, rigorous controlled clinical evidence for specific therapeutic dermatological outcomes of isolated docosanoic acid is lacking.

5.6 Antibacterial Activity

Behenic acid has shown antibacterial efficacy against bacteria including Acinetobacter baumannii, Staphylococcus aureus, and Pseudomonas aeruginosa. These organisms are clinically important, with A. baumannii and P. aeruginosa being major opportunistic pathogens. These findings are in vitro only and have not been developed into clinical antimicrobial applications.

Evidence Strength: Preclinical/in vitro only. No human data.

6. Body Systems Associated with Docosanoic Acid

Cardiovascular System: Involvement in serum cholesterol regulation, particularly LDL-C, documented in a small human crossover study.
Digestive / Metabolic System: Acts as an inhibitor of pancreatic lipase in structured triacylglycerol form; associated with increased fecal fat excretion in animal models.
Endocrine / Glycemic System: In silico evidence for FFA1 receptor agonism relevant to insulin secretion; observational inverse association with HbA1c and type 2 diabetes risk.
Nervous System / Neurology: Critical component of VLC-sphingolipids and ceramides in myelin; studied in relation to brain white matter pathology and neurodegeneration markers.
Integumentary System (Skin and Hair): Native component of stratum corneum; widely used as an emollient, moisturizer, and hair-smoothing agent in topical formulations.
Immune System: Potential modulation of TLR4/NF-κB inflammatory signaling based on in vitro and observational data.

7. Dosage Forms and Dosages Reported in Studies

Docosanoic acid is not widely marketed as an isolated dietary supplement, and no established or recommended daily intake has been defined by regulatory authorities such as the WHO, EFSA, or NIH. Relevant dosage information is available only from research contexts:

Human cholesterol study (Cater & Denke, 2001): In a randomized, crossover, metabolic-ward study, 7 mildly hypercholesterolemic men were fed three natural-food diets supplemented with behenate oil, palm oil, or high-oleic acid sunflower oil. Blood was drawn during the final 4 days of each 3-week diet period. The specific gram-per-day intake of behenic acid was not detailed in available source text.
Rodent anti-obesity study (Kojima et al., 2010): Rats were fed either BOO (1(3)-behenoyl-2,3(1)-dioleoyl-rac-glycerol) or soybean oil diet for 6 weeks, in which 20% of soybean oil was replaced with an experimental oil rich in BOO.
Mouse structured lipid study (Moreira et al., 2017): Twenty-four C57Bl/6 mice were distributed into four experimental groups according to the diet consumed: Control Diet (CD), Structured Lipids Diet (SLD), High-fat Control Diet (HCD), and High-fat Structured Lipids Diet (HSLD). The structured lipids were produced by enzymatic interesterification of olive oil, soy oil, and fully hydrogenated crambe oil containing behenic acid.
Postprandial inflammation study: Structured lipids with different contents of long-chain saturated fatty acids were synthesized through interesterification of soybean, peanut oils, and crambe hard fat. Structured lipids containing 23.79% (SL1), 32.01% (SL2), and 43.87% (SL3) of total saturated fatty acids reduced the absorption of serum triglycerides and appeared to mitigate postprandial inflammation.

In food sources, dietary exposure to docosanoic acid is typically low. It is a minor component of peanut oil (approximately 3.2 g per 100 g of oil), rapeseed (canola) oil, soybean oil, and moringa seed oil. Isolated supplemental forms are available as reagent-grade or technical-grade material for research use, not for therapeutic human administration.

8. Safety Considerations and Notable Interactions

General Toxicity

The oral LD50 for docosanoic acid in rats is greater than 2,000 mg/kg. Generally, the product does not irritate the skin. This classifies it as having low acute toxicity.

Most botanical oils are generally well tolerated in adults, with occasional allergic skin reactions occurring, and are "generally recognized as safe" (GRAS) as food (dietary supplement) by the U.S. Food and Drug Administration. Behenic acid, as a component of moringa and peanut oils used in food, has a long history of dietary exposure at low levels without recognized adverse effects at natural dietary intakes.

Cholesterol-Raising Effect

The most clinically significant safety signal identified in the peer-reviewed literature for dietary docosanoic acid is its potential to raise serum cholesterol. Behenic acid 22:0 can be found in ben (moringa) and peanut oils. Despite their low bioavailability, these fatty acids are cholesterol-raising agents in humans. Although docosanoic acid is reported to increase serum cholesterol levels, its low proportion and absorption in the intestines, low bioavailability, and low concentration in muscle does not pose any detrimental impact on human health at typical dietary intakes. This risk assessment, however, applies to naturally occurring dietary levels and may not extrapolate to higher supplemental doses.

Fecal Fat Excretion

In the structured lipid research context, behenic acid as a component of engineered triacylglycerols has been shown to increase fecal fat excretion. Animals that consumed structured lipids containing behenic acid showed lower weight gain due to a significant increase in lipids excreted in the feces, without any sign of toxicity or the presence of diarrhea. Whether similar gastrointestinal effects would manifest in humans at relevant doses is unknown.

Inhibition of Hepatic Fatty Acid Synthesis

Behenic acid is known to inhibit the synthesis of fatty acids in rat liver microsomes and to have biological properties such as the ability to induce hepatic steatosis. These are preclinical findings from rodent studies and have not been confirmed in human subjects.

Peanut Allergy Cross-Reactivity

Since docosanoic acid occurs naturally in peanut oil and skin, individuals with severe peanut allergy should be aware that products derived from peanut-sourced behenic acid could theoretically carry residual allergenic proteins, though purified behenic acid itself is not a protein allergen.

Topical Safety

Mild skin irritation such as redness or itching in very sensitive individuals; contact allergy leading to localized rash if a person is specifically allergic to behenic acid or other formulation components; and clogged pores or breakouts on acne-prone skin when used in high-occlusion leave-on products have been reported as potential adverse effects.

Regulation and Status

Docosanoic acid does not have an established specific regulatory monograph in the WHO, ESCOP, European Pharmacopoeia, or U.S. Pharmacopeia as an isolated medicinal substance. It is regulated indirectly as a component of approved food fats and cosmetic ingredients. In cosmetics, it carries the INCI name "Behenic Acid" and has CAS Number 112-85-6, Chem/IUPAC Name Docosanoic acid, EINECS/ELINCS No: 204-010-8, and COSING REF No: 74584.

9. Summary of Evidence Quality

Docosanoic acid (behenic acid) occupies an unusual position in the landscape of dietary fatty acids: it is simultaneously a well-characterized industrial and cosmetic ingredient with centuries of food exposure through its parent oils, yet a compound with a surprisingly sparse clinical evidence base for any specific health outcome. Its cholesterol-raising property in humans is documented in a single, very small randomized crossover trial. Its potential benefits in obesity, diabetes, and neurology rest on animal models, in silico calculations, and epidemiological associations — evidence that is preliminary and insufficient to establish therapeutic efficacy. The topical and cosmetic applications are industrially well-established, supported by biologically plausible rationale, but have not been subject to rigorous controlled clinical outcome trials. As of the available literature, no established therapeutic dose for docosanoic acid as an isolated supplement has been defined by any major health authority.